• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用抗原作图技术描绘二价加强后对 SARS-CoV-2 的中和特征。

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.

机构信息

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

University of Cambridge, Centre for Pathogen Evolution, Department of Zoology, Cambridge, UK.

出版信息

Nat Commun. 2023 Aug 26;14(1):5224. doi: 10.1038/s41467-023-41049-4.

DOI:10.1038/s41467-023-41049-4
PMID:37633965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10460376/
Abstract

Since emergence of the initial SARS-CoV-2 BA.1, BA.2 and BA.5 variants, Omicron has diversified substantially. Antigenic characterization of these new variants is important to analyze their potential immune escape from population immunity and implications for future vaccine composition. Here, we describe an antigenic map based on human single-exposure sera and live-virus isolates that includes a broad selection of recently emerged Omicron variants such as BA.2.75, BF.7, BQ, XBB and XBF variants. Recent Omicron variants clustered around BA.1 and BA.5 with some variants further extending the antigenic space. Based on this antigenic map we constructed antibody landscapes to describe neutralization profiles after booster immunization with bivalent mRNA vaccines based on ancestral virus and either BA.1 or BA.4/5. Immune escape of BA.2.75, BQ, XBB and XBF variants was also evident in bivalently boosted individuals, however, cross-neutralization was improved for those with hybrid immunity. Our results indicate that future vaccine updates are needed to induce cross-neutralizing antibodies against currently circulating variants.

摘要

自最初的 SARS-CoV-2 BA.1、BA.2 和 BA.5 变体出现以来,Omicron 已经发生了很大的变化。这些新变体的抗原特征分析对于分析它们潜在的免疫逃逸人群免疫力以及对未来疫苗成分的影响非常重要。在这里,我们描述了一个基于人类单次暴露血清和活病毒分离物的抗原图谱,其中包括广泛选择的最近出现的 Omicron 变体,如 BA.2.75、BF.7、BQ、XBB 和 XBF 变体。最近的 Omicron 变体聚集在 BA.1 和 BA.5 周围,有些变体进一步扩展了抗原空间。基于这个抗原图谱,我们构建了抗体图谱,以描述用基于原始病毒和 BA.1 或 BA.4/5 的二价 mRNA 疫苗进行加强免疫后的中和谱。BA.2.75、BQ、XBB 和 XBF 变体的免疫逃逸在二价加强免疫的个体中也很明显,然而,对于具有混合免疫的个体,交叉中和得到了改善。我们的结果表明,需要对未来的疫苗更新,以诱导针对当前流行变体的交叉中和抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/e0edf13938ef/41467_2023_41049_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/52865251f81e/41467_2023_41049_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/1f8211d1a26d/41467_2023_41049_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/f86ed6fb216b/41467_2023_41049_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/e0edf13938ef/41467_2023_41049_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/52865251f81e/41467_2023_41049_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/1f8211d1a26d/41467_2023_41049_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/f86ed6fb216b/41467_2023_41049_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a3b/10460376/e0edf13938ef/41467_2023_41049_Fig4_HTML.jpg

相似文献

1
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.用抗原作图技术描绘二价加强后对 SARS-CoV-2 的中和特征。
Nat Commun. 2023 Aug 26;14(1):5224. doi: 10.1038/s41467-023-41049-4.
2
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.感染前个体中针对 SARS-CoV-2 新兴奥密克戎亚变种的交叉中和抗体,同源 BNT162b2 或 BNT162b2(WT+BA.4/5) 二价加强针接种。
Virol J. 2024 Mar 21;21(1):70. doi: 10.1186/s12985-024-02335-9.
3
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.增强对奥密克戎亚谱系的中和作用:二价和单价 COVID-19 加强疫苗以及最近 SARS-CoV-2 奥密克戎变异株感染的相关见解。
Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000.
4
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.SARS-CoV-2 BA.4/5 感染在混合免疫背景下比 BA.1 引发更多的交叉反应性 FcγRIIIa 信号传导和中和作用。
J Virol. 2024 Jul 23;98(7):e0067824. doi: 10.1128/jvi.00678-24. Epub 2024 Jul 2.
5
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections.多次接种新冠疫苗以及反复感染奥密克戎非 JN.1 或 JN.1 毒株后的奥密克戎亚变体中和作用及抗原图谱分析
Sci Rep. 2025 Jan 9;15(1):1454. doi: 10.1038/s41598-024-84138-0.
6
Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.人类和仓鼠血清在鉴定 SARS-CoV-2 变体(包括 JN.1)中的抗原漂移方面具有良好的相关性。
J Virol. 2024 Nov 19;98(11):e0094824. doi: 10.1128/jvi.00948-24. Epub 2024 Oct 4.
7
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.比较携带早期和晚期 SARS-CoV-2 变异株刺突的单价和双价腺病毒疫苗的免疫原性。
Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.
8
Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.通过对 13 种 SARS-CoV-2 变体的交叉反应性分析进行免疫原性聚类的合理预测。
J Med Virol. 2024 Jan;96(1):e29314. doi: 10.1002/jmv.29314.
9
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
10
Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination.抗原图谱表明,在接种卫星五号疫苗后进行同源(卫星五号)或异源(Comirnaty)加强针后,奥密克戎 BA.1 和 BA.4/BA.5 变体与原始 SARS-CoV-2 仍然具有抗原差异。
Int J Mol Sci. 2023 Jun 22;24(13):10493. doi: 10.3390/ijms241310493.

引用本文的文献

1
Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022-2024: Evidence of immune heterogeneity.2022 - 2024年不同SARS-CoV-2奥密克戎暴露史人群血清的交叉中和作用:免疫异质性证据
One Health. 2025 Jul 17;21:101145. doi: 10.1016/j.onehlt.2025.101145. eCollection 2025 Dec.
2
SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion.基于刺突抗原性的严重急性呼吸综合征冠状病毒2血清分型及其对宿主免疫逃逸的影响
EBioMedicine. 2025 Apr;114:105634. doi: 10.1016/j.ebiom.2025.105634. Epub 2025 Mar 12.
3
Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression.

本文引用的文献

1
Mapping SARS-CoV-2 antigenic relationships and serological responses.绘制 SARS-CoV-2 抗原关系和血清学反应图。
Science. 2023 Oct 6;382(6666):eadj0070. doi: 10.1126/science.adj0070.
2
Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens.二价冠状病毒病 2019 疫苗对奥密克戎变异株的抗体反应表明,与匹配疫苗抗原的变异株反应会更好。
J Infect Dis. 2023 Aug 16;228(4):439-443. doi: 10.1093/infdis/jiad111.
3
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
血管炎相关免疫抑制患者对SARS-CoV-2疫苗的体液免疫反应。
Sci Adv. 2025 Feb 14;11(7):eadq3342. doi: 10.1126/sciadv.adq3342. Epub 2025 Feb 12.
4
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections.多次接种新冠疫苗以及反复感染奥密克戎非 JN.1 或 JN.1 毒株后的奥密克戎亚变体中和作用及抗原图谱分析
Sci Rep. 2025 Jan 9;15(1):1454. doi: 10.1038/s41598-024-84138-0.
5
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.一种二价新冠病毒mRNA疫苗引发了广泛的免疫反应并提供了针对奥密克戎亚变体感染的保护。
NPJ Vaccines. 2025 Jan 10;10(1):4. doi: 10.1038/s41541-025-01062-8.
6
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.15个实验室对新型冠状病毒抗原性的全球合作比较
Viruses. 2024 Dec 18;16(12):1936. doi: 10.3390/v16121936.
7
Nonhuman primate antigenic cartography of SARS-CoV-2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的非人灵长类动物抗原图谱
Cell Rep. 2025 Jan 28;44(1):115140. doi: 10.1016/j.celrep.2024.115140. Epub 2025 Jan 3.
8
Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic.新冠疫情期间严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的表型演变
Nat Microbiol. 2025 Jan;10(1):77-93. doi: 10.1038/s41564-024-01878-5. Epub 2025 Jan 3.
9
CovTransformer: A transformer model for SARS-CoV-2 lineage frequency forecasting.CovTransformer:一种用于预测SARS-CoV-2谱系频率的变压器模型。
Virus Evol. 2024 Nov 14;10(1):veae086. doi: 10.1093/ve/veae086. eCollection 2024.
10
Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.新冠病毒初次感染和突破性感染后血清免疫显性分析揭示了不同的变体特异性表位使用情况和免疫印记。
PLoS Pathog. 2024 Nov 18;20(11):e1012724. doi: 10.1371/journal.ppat.1012724. eCollection 2024 Nov.
BA.1 和 BA.4/BA.5 二价 SARS-CoV-2 加强免疫的免疫原性:COVAIL 随机临床试验的初步结果。
Clin Infect Dis. 2023 Aug 22;77(4):560-564. doi: 10.1093/cid/ciad209.
4
Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1.新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种BM.1.1.1、BQ.1.1和XBB.1的抗原图谱分析
Lancet Microbe. 2023 May;4(5):e294-e295. doi: 10.1016/S2666-5247(22)00384-6. Epub 2023 Jan 16.
5
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.二价奥密克戎 BA.1 适应型 BNT162b2 加强针在 55 岁以上成年人中的效果。
N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082.
6
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.BA.5二价mRNA疫苗加强针的免疫原性。
N Engl J Med. 2023 Feb 9;388(6):565-567. doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11.
7
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.令人担忧的 SARS-CoV-2 BQ 和 XBB 亚型不断出现的抗体逃逸特性。
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
8
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.来自mRNA二价加强针的针对BA.2.75.2、BQ.1.1和XBB的中和作用。
N Engl J Med. 2023 Jan 12;388(2):183-185. doi: 10.1056/NEJMc2214293. Epub 2022 Dec 21.
9
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.BA.2 和 BA.5 奥密克戎在免疫学上与 BA.1 奥密克戎和前奥密克戎变体不同。
Nat Commun. 2022 Dec 13;13(1):7701. doi: 10.1038/s41467-022-35312-3.
10
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.